Juvent, New National Osteoporosis Foundation Member, Exhibits at the Interdisciplinary Symposium on Osteoporosis on April 18-21
Palm Beach Gardens, F.L. (April 15, 2013) – Juvent, a Florida-based medical technology company with a leading focus in bone health, will exhibit its Juvent Dynamic Motion Therapy® platform at the National Osteoporosis Foundation’s (NOF) Interdisciplinary Symposium on Osteoporosis 2013 (ISO13) from April 18 to April 21, 2013 in Chicago. Juvent’s gentle, pulsing platform – the patented Juvent 1000N – offers a non-invasive musculoskeletal therapy and exercise methodology, that impacts bone. The Juvent technology is based on 20 years of academic and clinical research, backed by more than 100 published articles, and 34 in peer-reviewed journals. New research continues at St. Jude Children’s Hospital; Hebrew SeniorLife, affiliated with Harvard Medical School, and Children’s Hospital of Philadelphia.
Juvent is also proud to announce its recent appointment to the Corporate Advisory Roundtable of NOF. Rush Simonson, CEO of Juvent, said, “We are honored to be joining the conversation at the roundtable level, looking to generate innovation for the improvement of bone health, circulation and well-being in combating the effects of osteoporosis.” Juvent is one of only 19 members to have been selected for 2013. He added, “This symposium opportunity represents the first time we have exhibited at an NOF event as a Corporate Roundtable member, to explore the medical and clinical perspectives in medicine today. We are pleased to have forged a relationship with an organization that offers excellent support groups for patients and their families.”
ISO13 provides the most current, clinically relevant and evidence-based information on the prevention, diagnosis, and treatment of osteoporosis. Every 20 seconds, someone in the U.S. breaks a bone due to osteoporosis.
The ISO is unique in that it is the only professional meeting in the US that encompasses all medical disciplines and specialties involved in the treatment of patients with and at risk for osteoporosis and fractures.
Juvent has assembled an experienced management team of medical technology leaders, and experts in bone health and anti-aging. Juvent’s 20 years of research and development, 20 plus patents and more than $20 million invested in the company’s vision, has resulted in groundbreaking research and technologies to combat the effects of aging and poor bone health. Their patented “Dynamic Motion Therapy®” device, first to meet OSHA guidelines, safely using only 0.3g and 32 to 37 Hz mechanical signals, and has proven to be effective for exercise. The patented “Smart Technology” automatically calibrates the therapy to each patient’s body weight and mass.
The Juvent 1000 is available now in the U.S. and Taiwan, and soon in Canada, Europe, Australia and New Zealand. In the U.S., the Juvent 1000 device is an FDA recognized Class I medical device and the company plans to seek expanded FDA approval in the further areas of bone and joint health.